Financial Performance - The company's revenue for Q1 2023 reached ¥811,816,818, representing a 29.14% increase compared to ¥628,617,238 in the same period last year[3] - Net profit attributable to shareholders was ¥66,141,680, marking a 40.35% increase from ¥47,126,894 in Q1 2022[3] - The company reported a basic earnings per share of ¥0.54, up 42.11% from ¥0.38 in the same quarter last year[3] - Operating profit for Q1 2023 was ¥77,924,247.11, up from ¥54,916,990.14 in Q1 2022, reflecting a growth of 41.9%[23] - Net profit attributable to the parent company for Q1 2023 was ¥66,141,680.02, compared to ¥47,126,894.93 in Q1 2022, representing a year-on-year increase of 40.4%[23] - Total operating revenue for Q1 2023 reached ¥811,816,818, an increase of 29.1% compared to ¥628,617,238.94 in the same period last year[22] Cash Flow and Investments - The net cash flow from operating activities increased by 54.12% to ¥21,600,909 from ¥14,015,957 in the previous year[3] - The total cash inflow from operating activities for Q1 2023 was ¥634,636,626.42, an increase of 22.3% compared to ¥518,954,386.03 in Q1 2022[24] - Cash outflow from investment activities totaled ¥401,060,831.39, a decrease of 18.4% from ¥491,727,786.23 in Q1 2022[25] - The net cash flow from investment activities was -¥401,062,190.31, compared to -¥491,734,373.18 in the previous year, indicating a reduction in cash outflow[25] - Cash inflow from financing activities was ¥42,452,002.44, with a net cash flow of ¥39,276,135.89, compared to a net outflow of -¥3,094,585.68 in Q1 2022[25] - The ending cash and cash equivalents balance was ¥237,039,230.28, significantly higher than ¥124,832,105.75 at the end of Q1 2022, marking an increase of 89.9%[25] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥2,306,025,264.82, an increase of 8.68% from ¥2,121,755,885.67 at the end of the previous year[3] - Total liabilities at the end of Q1 2023 were ¥753,233,707.58, an increase from ¥641,534,824.26 at the beginning of the year, reflecting a rise of 17.4%[19] - Current assets totaled ¥1,557,043,251.17 at the end of Q1 2023, compared to ¥1,452,547,083.20 at the beginning of the year, marking an increase of 7.2%[18] - Long-term equity investments increased significantly to ¥43,735,288.33 from ¥14,397,960.96, showing a growth of 203.5%[18] - The total equity attributable to the parent company increased to ¥1,552,791,557.24 from ¥1,480,221,061.41, representing a growth of 4.9%[20] Operational Highlights - The company experienced a 45.13% increase in accounts receivable, rising to ¥46,576,730 due to increased sales and credit terms[7] - The company’s operating costs rose by 34.70% to ¥51,519,690, corresponding to the revenue growth in the pharmaceutical sector[8] - The company received government subsidies amounting to ¥843,372.06 during the quarter, which is a decrease compared to previous periods[4] - The company received acceptance for the consistency evaluation of Metformin and Glimepiride tablets, and the registration application for Paliperidone raw materials[13] - The company approved the launch of Venlafaxine sustained-release tablets and Oxycodone sustained-release tablets during the reporting period[13] - The company participated in the national centralized procurement bidding for Nifedipine sustained-release tablets but did not win due to pricing factors[13] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,061[10] - The company’s top ten shareholders include various investment funds and individuals, with the largest shareholder holding 4,131,220 shares[12] Corporate Actions - The company is planning a major asset restructuring involving its wholly-owned subsidiary, Anhui Lifan Pharmaceutical Co., Ltd., to introduce new investors[14] - The company’s board approved the asset sale proposal related to Anhui Lifan Pharmaceutical on March 17, 2023[15] - The company held its first extraordinary general meeting of 2023 on March 31, 2023, to approve the asset sale and capital increase proposals[16] Miscellaneous - The report for Q1 2023 was not audited, indicating that the figures may be subject to change upon final review[26]

Group 1: Product Development and Approval - The company is in the final negotiation stage for a significant growth opportunity related to the acquisition of ophthalmic drugs, with a focus on promoting specific eye drop products like "Jin Zhen" and "Pyridostatin Potassium" [1] - The approval for "Nifedipine Controlled-Release Tablets" has been submitted and is expected to be approved this year after passing the production site inspection in March [1] - The production capacity for "Yiqi Hewei Capsules" is nearly saturated, with a new production line expected to be operational in the second half of the year [1] Group 2: Market Strategy and Sales Growth - The company aims to increase its investment in ophthalmic formulation R&D and plans to establish its own ophthalmic production line [1] - The growth potential for essential drugs in hospitals remains significant, with a target for basic drug distribution in healthcare institutions to reach at least 90% [1] - The sales channels for "Clindamycin Gel" include both hospitals and retail [2] Group 3: Business Focus and Future Planning - The company will continue to focus on its pharmaceutical industrial sector while improving the operational quality of its pharmaceutical commercial segment, primarily within the province [4]

合肥立方制药股份有限公司 投资者关系活动记录表 证券代码：003020 证券简称：立方制药 编号：2021-002 | --- | --- | --- | |-----------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

合肥立方制药股份有限公司 投资者关系活动记录表 证券代码：003020 证券简称：立方制药 编号：2022-001 | --- | --- | --- | --- | |--------------------------|-----------------------------|-------------|---------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 | □分析师会议 | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 华创证券：高岳 | | 张泉 | | 时间 | 2022-1-11 10 ： 30 | | | | | 地点 立方营销大楼五楼会议室 | | | | 上市公司接待 人员姓名 | 生 | | 副董事长、总 ...

Group 1: Product Development and Market Position - The company anticipates that the sustained-release nifedipine tablets may be included in the seventh batch of national centralized procurement, while other products are not yet eligible for centralized procurement [1] - The Yiqi Hewei capsules, developed by Jiangsu Provincial Hospital, saw a year-on-year sales growth of 137.98% in 2020 and maintained a good growth trend in 2021 [1] - The company has developed its own laser perforation equipment for the preparation of permeation pump formulations, in addition to purchasing domestic and imported equipment [1] Group 2: New Product Pipeline - The company has obtained approval for several new products in 2021, including sustained-release tramadol hydrochloride tablets, sustained-release nifedipine tablets, and raw materials for methylphenidate hydrochloride [2] - The company is planning to continue investing in innovative drugs for controlled-release formulations and ophthalmic medications based on its existing product lines [2] - The company has received 13 approvals for ophthalmic products in 2021 and is also initiating new projects based on existing products [2] Group 3: Competitive Advantage - The company is recognized for its industrialization capabilities in complex formulations, currently having four products on the market, including sustained-release nifedipine tablets and sustained-release doxazosin mesylate tablets [2] - There are five products in the registration review stage, including sustained-release venlafaxine tablets [2] - The company aims to strengthen its core competitiveness by further industrializing complex controlled-release formulations and integrating them with narcotic drugs [2]

Group 1: Market Overview - The ophthalmic product market is expanding, with a significant consumer attribute, and sales are less affected by centralized procurement [1] - The company has acquired 13 varieties of eye drops, including Jin Zhen eye drops and others, which are actively promoted [1] Group 2: Research and Development - The company is developing innovative drugs based on antibody fusion proteins, with promising animal trial results [1] - There is ongoing development of complex formulations using the company's permeation pump technology [1] - The company is also focusing on traditional Chinese medicine and has initiated several projects in this area [1] Group 3: Shareholder Actions - One supervisor disclosed a reduction of over 300,000 shares, with a plan not exceeding 75,900 shares, indicating minimal impact [2] - Institutional shareholders hold a total of 3.48 million shares, accounting for 5.01% of the company's total share capital [2] Group 4: Product Strategy - The company plans to innovate in the field of controlled substances, with several products in the registration phase [2] - The Yiqi Hewei capsule has seen rapid growth due to its status as a unique essential drug, with significant potential for further sales growth [2] Group 5: Sales and Marketing - The sales team is structured into clinical and OTC channels, with a specialized team for ophthalmic products [4] - The company does not currently have major products participating in centralized procurement [4] Group 6: Future Outlook - The company anticipates maintaining good sales growth for Felodipine sustained-release tablets, which are not yet subject to centralized procurement [3] - The first batch of Nifedipine controlled-release tablets is ready for market, with centralized procurement expected to occur in March-April [3]

合肥立方制药股份有限公司 2022 年第三季度报告 证券代码：003020 证券简称：立方制药 公告编号：2022-067 合肥立方制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上 | 年初至报告期 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 年同期增减 | 末 | 比上年同期增减 | | 营业收入（元） | 664,961,110.68 | 12.50% | 1,894,187,478.90 | 13.77% | | 归属于上市公司股东的净利润 （元） | 72,379,559.25 | 73.33% | 170,549,504.37 | 36.07% | | 归属于上市公司股东的 ...